First-in-human percutaneous transseptal Retrieveal of Embolized TRanscatheter valve In the lEft VEntricle (RETRIEVE) Now in press in JACC CVI Thank you to the patient/family and the Morristown team for the trust and support in me for this great save. Philippe Genereux

Presented in the 🔥HOTline 6 in main room at the #ESCCongress and sim pub in #JACC 💊Our PULSE RCT 🌐606 patients with LM PCI 🏥6-months routine CCTA vs standard FU Compared to standard FU: 📌CCTA group ↔️MACE 📌CCTA group ⬇️Spontaneous MI Full paper 👉🏻jacc.org/doi/10.1016/j.…

Routine CT angiography after #PCI for left #cvCAD did not reduce the risk of major adverse CV events, according to the PULSE trial presented at #ESCCongress and published in #JACC. Get the details with TCTMD: bit.ly/4m2W921

How can intravascular imaging best guide left main stenting? - Evolving MSA cut-off values, their prognostic implications, and the nuances in interpretation. eurointervention.pcronline.com/article/evolvi…

EACTS Joint session with #EAPCI Defining optimal revascularization..from guidelines to the OR/cathlab A consistent theme is the heart team & evidence for said strategy EAPCIPresident chief Valeria Paradies women IC in the lion’s den 🤪..a pleasure discussing with

The DOUBLE-TAP study highlighted the value of post-dilatation in TAVI. Darren Mylotte & Soh discuss how a “double-tap” can optimise THV expansion and outcomes. #TAVI #StructuralHeart Editorial 👉eurointervention.pcronline.com/article/just-t… Main paper by 👉shorturl.at/FQTE6

In severe rheumatic MS, low-flow status is associated with worse clinical outcomes regardless of mean mitral gradients. #AHAJournals NUHCS - National University Heart Centre,Singapore ahajrnls.org/4qc3iAF

Statin efficacy to decrease #MACE depends on #CAD phenotypes and increases with the extent and severity of disease and in the presence of high-risk plaques. Patients without CAD have no benefit from statin therapy regarding MACE. jacc.org/doi/10.1016/j.… #JACCIMG #cvCAD

HOST-BR published in The Lancet: 1-month DAPT failed to meet non-inferiority compared with 3-months DAPT among ARC-HBR patients (due to ischemic hazard). 3-months DAPT was superior to 12-months DAPT among patients without ARC-HBR criteria (due to bleeding benefit). (DAPT

The DOSE Trial: In a multicenter RCT (n=1,001), operator radiation exposure was compared between left distal radial vs right transradial access at left wrist, head, and chest. No significant differences. jacc.org/doi/10.1016/j.… #TCT2025 #JACCINT

From #TCT2025 San Francisco The #ReTAVI Registry, the first prospective redo-TAVR study, presented by Prof. Giuseppe Tarantini, reports: 🔹 VARC-3 device success: 95% 🔹 30-day all-cause mortality: 3.5%, Stroke & TIA: 0.7% 🔹 Coronary obstruction: 1.4%, new pacemaker: 6.3% 🔹

💥 The #ShortCUT Trial at #TCT2025: In imaging-guided PCI of calcified lesions, cutting balloon angioplasty was non-inferior to intravascular lithotripsy (IVL) for stent expansion and MSA with significantly lower procedural cost. A pragmatic study with important

💥 The #VICTORY Trial presented at #TCT2025: In OCT-guided PCI for severely calcified coronary lesions, OPN non-compliant balloon was non-inferior to intravascular lithotripsy (IVL) for stent expansion — with fewer devices, shorter procedures, and lower cost. #TCT2025

Results from #SELUTION are encouraging, but some aspects deserve attention: 👇 1️⃣ Observed TVF rate of 4.4% (DES) was lower than expected (assumed rate 6%) 2️⃣ 50% non-inferiority margin is somewhat large. With a more conservative approach, including a 33% margin, non-inferiority

Surprisingly DOAC has lower bleeding vs DAPT.

Dr Josep Rodes-Cabau presenting Late-Breaking Clinical Science at Main Arena: #ANDES (Short-Term Anticoagulation Versus Anti-platelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure #LAAC #LAAO) Trial Cardiovascular Research Foundation #TCT2025 IUCPQ-ULaval Dan Burkhoff MD PhD

Initial testing choice between coronary CTA and stress testing for suspected CAD showed no difference in all-cause or cardiovascular mortality among patients with stable symptoms. ja.ma/47fvIlE

And now, the curves we’ve all been waiting to see — those of TAVI and surgery in PARTNER 3 at 7 years: it’s an even match across the board, I would say, although I still can’t quite understand why there are so many more surgical patients lost to follow-up. #TCT2025

The future is here and interventional Cardiologists are fed up of blindly stenting irrelevant lesions! This is why those sessions are jam packed. Carlos Collet MD PhD CoreAalst Yader Sandoval Cardiovascular Research Foundation #TCT2025 James Spratt

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone